What is the current H3N2 flu outbreak situation in Europe as of December 2025?
This fact-check may be outdated. Consider refreshing it to get the most current information.
Executive summary
Europe is experiencing an early, H3N2-dominated 2025–26 influenza season driven largely by a drifted H3N2 “subclade K,” which accounts for about one‑third of global H3N2 sequences and almost half of H3N2 sequences in the EU/EEA between May–Nov 2025 (ECDC) [1]. Clinical impact varies: several countries (UK, Spain, Ireland, Romania, Hungary) report sharp rises in cases and hospital admissions, while WHO/Europe and ECDC say there is no clear evidence yet that the virus causes more severe disease than usual but vigilance and vaccination are recommended [2] [3] [1].
1. Early and widespread: subclade K is now dominant in many places
Public-health sequencing shows A(H3N2) subclade K has expanded rapidly this year, representing roughly a third of global H3N2 sequences submitted to GISAID between May and November 2025 and almost half of H3N2 sequences in the EU/EEA—evidence that this genetic offshoot is broadly established across Europe and beyond [1] [4]. WHO reports A(H3N2) became the predominant influenza A subtype in the northern hemisphere by late September, reinforcing that H3N2 is driving the current season [5].
2. Clinical picture: more cases and earlier peaks, but not clearly more severe
Several countries are seeing large, early increases in influenza cases and hospitalisations: the UK’s hospitals reported a 50–55% week‑on‑week jump in flu patients in early December and predictions of rising admissions; Spain, Ireland, Romania and Hungary have recorded surges too [6] [2] [7]. International agencies caution, however, that while subclade K appears to spread earlier and faster, available reports from east Asia and ECDC’s analysis do not show evidence so far of consistently increased disease severity compared with previous H3N2 seasons [1] [5].
3. Vaccine mismatch and effectiveness: a significant caveat
Genetic changes in subclade K mean it is antigenically drifted from the H3N2 strain chosen for the 2025–26 Northern Hemisphere vaccine, prompting concerns that vaccine protection against this specific H3N2 lineage will be reduced [8] [9]. National data provide nuance: early UK estimates suggest vaccines still protect—particularly in children—against hospital attendance, but antigenic diversity among circulating H3N2 viruses means ongoing monitoring of effectiveness is required [6] [10].
4. Who is most affected: children, closed settings and the elderly
Reports indicate this early H3N2 season is hitting children hard and stressing paediatric and general hospital capacity in parts of Europe, while ECDC flags that closed settings (long‑term care facilities) remain at heightened risk for outbreaks with high morbidity and mortality [11] [1]. H3N2 historically hits older adults harder, which is why health agencies are urging vaccination of high‑risk groups [11] [10].
5. Public‑health response and projections: vigilance, vaccination and healthcare strain
WHO/Europe expects the season to peak in late December or early January, with positivity potentially around 50%, and is calling for vigilance, vaccination and layered protections [3]. ECDC has issued threat assessments urging monitoring and preparedness; the UK has reported critical pressure on services and warned of worst‑case scenarios without mitigations [1] [7].
6. Competing narratives and misinformation risks
Some outlets use alarmist language—“super flu” or “worst flu in decades”—which can conflate faster spread and vaccine drift with higher intrinsic severity; ECDC and WHO temper that narrative by saying subclade K is widespread but not conclusively more virulent than prior strains [12] [1] [5]. Readers should note differences in emphasis: national news coverage often stresses immediate healthcare strain (UK press, hospital figures) while ECDC/WHO focus on surveillance data and uncertainty about severity [6] [1] [5].
7. Practical takeaway for readers in Europe
Public-health bodies across Europe advise eligible people to get vaccinated, use standard respiratory protections (masking if unwell, hand hygiene, ventilation), and for healthcare services to prepare for higher admission volumes; these are consistent recommendations from WHO/Europe and national agencies [3] [10]. Genomic surveillance will determine how much vaccine effectiveness is affected and whether the clinical picture changes; current data call for caution but not panic [1] [6].
Limitations: available sources from WHO, ECDC and national reporting provide the core epidemiology and sequencing picture, but detailed country‑by‑country case counts, age‑specific severity metrics and up‑to‑date vaccine effectiveness figures are variably reported in these documents and evolving week to week—readers should consult national public‑health updates for the latest local data [6] [5] [1].